Ben Fidler (Xconomy.com)
There are tough targets in drug development, and then there’s p53. It’s a holy grail, of sorts, in cancer biology—a tumor suppressor protein that gets shut down in some form in every known type of cancer. Yet every company that’s tried to protect it with a drug has failed for one reason or another.
Over the past few years, however, the tall order of shielding p53 has become the top priority of Cambridge, MA-based Aileron Therapeutics. And despite the risks, the potential reward has led to a lot of investor backing—including a fresh new round of cash today. Read more on Xconomy